Avammune Therapeutics Company Profile

Background

Avammune Therapeutics, founded in 2020, is a biopharmaceutical company dedicated to developing small molecule therapies that modulate the innate immune system to treat cancer and autoimmune diseases. The company's mission is to harness the body's natural defenses to combat malignancies and immune-related disorders, aiming to provide accessible and effective treatments. Operating out of Philadelphia, USA, and Bengaluru, India, Avammune integrates novel target biology, immunology, computational chemistry, and high-throughput chemistry to identify and develop proprietary small-molecule drug candidates.

Key Strategic Focus

Avammune's strategic focus centers on:

Innate Immunity Modulation: Developing therapies that activate the body's first line of defense to recognize and eliminate cancer cells.

Small Molecule Drug Development: Creating orally bioavailable small molecules targeting key immune pathways, offering advantages over biologics in terms of administration and accessibility.

Oncology and Autoimmune Disorders: Addressing unmet medical needs in cancers such as osteosarcoma, Ewing’s sarcoma, triple-negative breast cancer, and gastrointestinal cancers, as well as various autoimmune diseases.

Financials and Funding

Avammune has successfully secured funding to advance its research and development:

Series A Funding (May 2025): Raised $12 million (approximately ₹100 crore) in a round co-led by Capital 2B, Shastra VC, and Kotak Lifesciences Fund I, with participation from IvyCap Ventures and 1Crowd.

The capital is intended to:

Accelerate the clinical development of lead candidate AVA-NP-695.

Support preclinical work on other pipeline candidates.

Strengthen the company's intellectual property portfolio.

Pipeline Development

Avammune's pipeline includes:

AVA-NP-695 (ENPP1 Inhibitor): An orally available ENPP1 inhibitor demonstrating strong antitumor efficacy in preclinical models for cancers such as osteosarcoma, Ewing’s sarcoma, and triple-negative breast cancer. It has also shown promise in veterinary cancer patients under compassionate use.

AVA-ADR Series (ADAR1 Inhibitors): Developing small molecule inhibitors targeting the ADAR1 enzyme, with AVA-ADR-001 showing significant interferon response and antitumor activity in preclinical studies.

Technological Platform and Innovation

Avammune's innovation is characterized by:

Proprietary Technologies: Development of a chemical library targeting DNA/RNA-binding proteins, enabling the creation of highly targeted therapies at lower doses.

Scientific Methodologies: Utilizing computational chemistry and high-throughput screening to identify novel targets and develop small-molecule drug candidates.

Leadership Team

Arun B. Papaiah: Founder and Chief Executive Officer. Co-founded Aten Porus Lifesciences, Oraxion Therapeutics, and Avaliv Therapeutics. Holds an MBA from the Royal Melbourne Institute of Technology and a B.Sc. from Christ University.

Dr. Aditya Kulkarni: Founder and Chief Scientific Officer. Co-founded Aten Porus Lifesciences, Oraxion Therapeutics, and Avaliv Therapeutics. Holds a Ph.D. in Bioorganic Chemistry from Purdue University, an M.S. in Chemical Biology from Leeds University, and a B.Sc. in Chemistry from Christ University.

Srinivasan Namala: Founder and Director. Co-founded Aten Porus Lifesciences and Oraxion Therapeutics. CEO of Porus Labs. Holds an M.S. in Pharmaceutics from Northeastern University and a B.Pharm from BITS Pilani.

Leadership Changes

As of July 15, 2025, there have been no recent significant changes or appointments within Avammune's leadership team.

Competitor Profile

Market Insights and Dynamics

The global immuno-oncology market is valued at approximately $100 billion and is projected to grow at a compound annual growth rate (CAGR) of 17%, driven by increasing cancer incidence and demand for novel therapies.

Competitor Analysis

Key competitors include:

Aclaris Therapeutics: Specializes in developing dermatologic therapies.

Altogen Labs: A GLP-compliant laboratory offering preclinical research services.

Strategic Collaborations and Partnerships

Avammune is in advanced discussions with major pharmaceutical and biotech companies for partnerships to advance its pipeline through clinical development.